BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Week in Review: Singapore's S*Bio Sells Cancer Drug to US Pharma


8/13/2012 9:04:13 AM

by Richard Daverman, PhD

August 11, 2012 -- S*BIO of Singapore sold worldwide rights for a Phase III-ready HDAC inhibitor, intended for hematologic disorders, to MEI Pharma of San Diego; PharmaEngine of Taiwan acquired Asia-Pacific rights (including China) to a radiology-enhancing nanomedicine product from Nanobiotix S.A., a French company; Takeda Pharma officially opened its new headquarters for China clinical trials in Shanghai; Mindray Medical reported Q2 revenues climbed 23% to $267.8 million, handily beating expectations; and Biostar Pharma of Xianyang warned investors that its second quarter revenues will be 50% lower than Q1 because it shut down production of gelatin-based capsules. More details….

Stock Symbols: (NSDQ: MEIP) (TWO: 4162) (TSE: 4502) (NYSE: MR) (NSDQ: BSPM)


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->